Aggressive Smoking Cessation Trial (ASAP)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 798 participants.
Also called NCT05257629
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 798 participants
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Registry
-
NCT05257629
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT05257629. Randomized; no masking; primary purpose prevention. Start 2023-02-02 (actual); primary completion 2026-03-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Aggressive Smoking Cessation Trial (ASAP)
- Acronym
- ASAP
- Condition
- Acute Coronary Syndrome
- Condition
- Cardiovascular Diseases
- Intervention (Combination product)
- Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)
- Intervention (Other)
- Varenicline Plus Counseling
- Lead sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Record details
- Record id
cardio:ct-nct05257629- Content hash
cccbc5fe3eb0a49e53b15edf95316f69de50fbefcdd4aa4dc2dbf9e5467b5f44